drugset / Trial / NCT00638157

Phase 4 Efficacy and Safety Study of Cubicin® With and Without Combination Therapy in S. Aureus Infective Endocarditis (SAIE)

NCT00638157

Phase 4 Terminated 24 enrolled Merck & Co., Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

multicenter, randomized, double blind study to describe the safety and efficacy of daptomycin (6 mg/kg q24h) with and without concomitant initial gentamicin combination therapy in the treatment of SAIE

Timeline

Start
2009-02-13
Primary completion
2011-11-09
Completion
2011-11-09

Drugs

EvaluationDrugModalityDoseRoute
Comparator Daptomycin Other / unclassified 6 mg/kg Intravenous
Subject Gentamicin Small molecule Intravenous